Excellent — I now have all the key content and images needed for a comprehensive answer.
Management of Hypotension
Hypotension (SBP < 90 mmHg or MAP < 65 mmHg, or a ≥40 mmHg drop from baseline) can reflect shock — a state of inadequate oxygen delivery to tissues. Management is guided by the underlying type of shock, and the goal is always restoration of tissue perfusion, not merely a blood pressure number.
Step 1: Classify the Type of Shock
Understanding the hemodynamic profile determines the correct treatment.
Goldman-Cecil Medicine — Causes, cardiovascular findings, and hemodynamic support for different shock types.
| Type | Examples | Preload | Contractility | Afterload |
|---|
| Hypovolemic | Hemorrhage, GI bleed, dehydration | ↓ | ↑ (compensatory) | ↑ |
| Cardiogenic | MI, myocarditis, arrhythmia | ↑ | ↓ | ↑ |
| Obstructive | PE, tamponade, tension pneumothorax | ↓ | ↓ | ↑ |
| Distributive | Sepsis, anaphylaxis, neurogenic | ↓ | ↑/variable | ↓ |
General Principles (All Shock Types)
- Airway & Oxygenation: Supplemental O₂ for all patients. Intubate early for severe hypotension, acidosis, or respiratory distress — do not delay for a trial of non-invasive ventilation.
- IV access: Large-bore peripheral or central access.
- Monitor: Arterial line for continuous BP; consider right heart catheterization when starting vasoactive agents in cardiogenic shock.
- Treat the cause: The definitive intervention is always etiology-specific (e.g., PCI for cardiogenic shock from MI, decompression for tension pneumothorax, source control for sepsis).
1. Hypovolemic Shock
Cornerstone: fluid resuscitation
- Isotonic crystalloids (normal saline or Ringer's lactate) — at least 30 mL/kg IV in sepsis-induced hypoperfusion; guided by hemodynamic response in hemorrhagic shock.
- Blood products for hemorrhage: packed RBCs; balanced transfusion (1:1:1 ratio of RBC:FFP:platelets) in massive hemorrhage.
- Vasopressors may be needed transiently while resuscitation proceeds but carry caution (increase afterload, risk of ischemia if underfilled).
- Control the source of bleeding.
2. Cardiogenic Shock
Cornerstone: restore myocardial perfusion + pharmacological support
- Small fluid bolus may be tried cautiously — but aggressive fluids worsen pulmonary edema.
- Vasopressors & Inotropes (titrated to BP and mixed venous O₂ saturation):
| Agent | Dose | Mechanism | Role |
|---|
| Norepinephrine | 0.02–1.0 µg/kg/min | α1 + mild β1 | Preferred vasopressor for cardiogenic shock; increases coronary flow |
| Dopamine | 3–10 µg/kg/min (inotrope); 10–20 µg/kg/min (vasopressor) | DA/β1/α1 | Second-line; more arrhythmias than NE |
| Dobutamine | 2.5–20 µg/kg/min | β1 selective | Inotrope of choice when SBP >90 mmHg; may worsen hypotension |
| Milrinone | 0.125–0.75 µg/kg/min (no load) | PDE inhibitor | Equivalent to dobutamine; long half-life, risk of hypotension |
| Epinephrine | 0.05–2 µg/kg/min | α + β | Reserve for refractory hypotension; more metabolic derangement |
| Vasopressin | 0.02–0.04 U/min | V1 receptor | Catecholamine-refractory cases |
- Revascularization (PCI) is the only intervention that consistently reduces mortality in cardiogenic shock from acute MI — outcomes are best within 6 hours of onset.
- Intra-aortic balloon pump (IABP): reduces systolic afterload, augments diastolic perfusion pressure — randomized trials show no mortality benefit with routine use; reserved for bridging to definitive therapy.
- Mechanical circulatory support (e.g., LVAD) if IABP fails.
3. Obstructive Shock
Cornerstone: relieve the obstruction
- Tension pneumothorax: immediate needle decompression → chest tube.
- Cardiac tamponade: pericardiocentesis.
- Massive PE: thrombolysis or catheter-directed therapy (systemic tPA if no contraindications); anticoagulation.
- Vasopressors and volume expansion are temporizing measures only.
4. Distributive Shock (Septic/Neurogenic/Anaphylactic)
Septic Shock
Surviving Sepsis Campaign (2016 guidelines, still in wide use):
| Priority | Intervention |
|---|
| 1st | IV crystalloid ≥30 mL/kg + norepinephrine as first vasopressor |
| 2nd | Add vasopressin (0.03 U/min) when NE dose escalates (0.25–0.5 µg/kg/min) |
| 3rd | Epinephrine as third agent |
| Adjunct | Hydrocortisone 200 mg/day if ongoing vasopressor requirement |
| Low CO component | Add dobutamine to NE, or switch to epinephrine |
- Norepinephrine is preferred over dopamine — the SOAP II trial (1679 patients) showed similar mortality but significantly more arrhythmias with dopamine; subgroup analysis showed improved survival with NE in cardiogenic shock.
- In vasodilatory shock, a target MAP of 65 mmHg is standard; lowering the target to 60–65 mmHg by reducing vasopressors is not clearly superior to standard care.
- Permissive hypotension strategies should be applied cautiously.
Anaphylactic Shock
- Epinephrine IM (0.3–0.5 mg, 1:1000) into the lateral thigh — first-line.
- IV fluids for volume depletion.
- Antihistamines (H1 + H2), corticosteroids as adjuncts.
- Second dose of epinephrine if no response within 5–15 min.
Neurogenic Shock (spinal cord injury)
- IV fluids first.
- Vasopressors (norepinephrine or phenylephrine) to restore vascular tone.
- Target MAP 85–90 mmHg for the first 7 days in acute spinal cord injury.
5. Orthostatic Hypotension (Chronic / Non-Shock)
The goal is symptom control, not a BP target.
Goldman-Cecil Medicine — Stepwise approach to orthostatic hypotension.
Non-pharmacologic (first-line):
- Change positions gradually; sit briefly before standing.
- Increase fluid intake (2–2.5 L water/day) and salt (1–2 tsp daily or salt tablets 0.5–1.0 g).
- Avoid hot environments, alcohol, large carbohydrate-rich meals.
- Physical countermaneuvers: leg crossing, squatting, calf raises.
- Compression stockings (≥15–20 mmHg) or abdominal binder.
- Bolus water drinking (500 mL) for acute rescue — pressor effect within 5–10 min.
- Elevate head of bed 30–45°.
Pharmacologic:
| Drug | Dose | Mechanism | Notes |
|---|
| Fludrocortisone | 0.1–0.2 mg/day PO | Mineralocorticoid — expands volume | First-line with volume depletion; takes ≥7 days to work; watch for supine hypertension, hypokalemia |
| Midodrine | 5–10 mg TID PO | α1 agonist — arteriolar/venous constriction | Take before rising, before lunch, ≥3–4h before bedtime |
| Droxidopa | 100–600 mg TID PO | Converted to NE peripherally | Same timing as midodrine; for neurogenic OH |
| Pyridostigmine | 30–60 mg TID PO | AChE inhibitor — enhances ganglionic transmission | Increases standing BP without causing supine HTN |
| Atomoxetine | 10–18 mg BID PO | NE reuptake inhibitor | Best when sympathetic terminals preserved (MSA) |
| Acarbose | 50–100 mg before meals | Delays carbohydrate absorption | Adjuvant for postprandial hypotension |
| Octreotide | 0.2–0.4 µg/kg SQ | Splanchnic vasoconstriction | Adjuvant for postprandial hypotension |
| Erythropoietin | 25–75 U/kg SQ 3×/week | Increases RBC mass | When anemia contributes |
Key Vasopressor Drug Comparison Summary
| Drug | Receptor | Primary Effect | Best Use |
|---|
| Norepinephrine | α1 > β1 | Vasoconstriction + mild inotropy | First-line for distributive & cardiogenic shock |
| Vasopressin | V1 | Vasoconstriction | Second-line add-on to NE in septic shock |
| Dopamine | DA > β > α | Dose-dependent: inotrope/vasopressor | Second-line; avoid if arrhythmia risk |
| Dobutamine | β1 | Inotropy | Cardiogenic shock with adequate BP |
| Epinephrine | α + β | Vasoconstriction + inotropy | Anaphylaxis (1st line); refractory shock |
| Phenylephrine | α1 | Pure vasoconstriction | Neurogenic shock; avoid in low CO states |
| Milrinone | PDE inhibitor | Inotropy + vasodilation | Cardiogenic shock; beware of hypotension |
Sources: Goldman-Cecil Medicine (9780323930345) | Fuster & Hurst's The Heart, 15th Ed. (9781264257560) | Harrison's Principles of Internal Medicine 22E (9781265977061) | Washington Manual of Medical Therapeutics (9781975190620)